Ductal Adenocarcinoma Of The Prostate: Clinical Features And Implications After Local Therapy

Main Category: Prostate / Prostate Cancer
Also Included In: Urology / Nephrology;  Cancer / Oncology
Article Date: 12 Jul 2009 - 0:00 PDT

Current ratings for:
'Ductal Adenocarcinoma Of The Prostate: Clinical Features And Implications After Local Therapy'

Patient / Public:3 stars

3 (1 votes)

Healthcare Prof:3 stars

3 (1 votes)


UroToday.com - On occasion, urologists will encounter subtypes of prostate cancer (CaP) other than adenocarcinoma. One such subtype is ductal (or endometrioid) CaP. Ductal CaP is characterized by the presence of tall, pseudostratified columnar cells with abundant cytoplasm arranged in a papillary pattern. It can be diagnosed with high Gleason score and advanced stage, but its clinical course has been relatively undefined. In the online version of Cancer, Dr. Shi-Ming Tu and colleagues report a series of 108 patients with ductal CaP.

Clinical and pathological variables were retrospectively assessed in these 76 patients who had undergone radical prostatectomy (RP) or the other 32 non-surgical patients who had primarily received radiotherapy. Seventy-five surgical patients were evaluable with a median follow-up of 4.9 years. Interestingly 79% of the men who received a diagnosis of ductal CaP were found to have this subtype in the RP specimen, as opposed to detection on the initial prostate biopsy. Ten men had pure ductal subtype, 15 men had predominately ductal subtype and the other 50 patients had mixed ductal and acinar CaP. PSA, age, stage and Gleason score did not differ between the pure and mixed pathology groups.

The median overall survival was 13.8 years for the pure histological group and 8.9 years for the mixed group. The median time to local progression was 2.8 years vs. 4.9 years and the median time to distant metastasis was 3.9 years vs. 2.0 years for patients who had pure ductal CaP vs. mixed ductal CaP of the prostate after RP, respectively. The majority of the non-surgical group was diagnosed by TURP and the median delivered radiotherapy dose was 70 Gy. Median overall survival for the non-surgical group was 8.2 years. The authors conclude that the increased local progression rate in the pure ductal CaP group supports a role for RP as the best option for local control.

Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL
Cancer. 2009 Apr 28. Epub ahead of print.
doi:10.1002/cncr.24326

Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2009 - UroToday

Article adapted by Medical News Today from original press release.
Visit our prostate / prostate cancer section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Urotoday. "Ductal Adenocarcinoma Of The Prostate: Clinical Features And Implications After Local Therapy." Medical News Today. MediLexicon, Intl., 12 Jul. 2009. Web.
25 May. 2012. <http://www.medicalnewstoday.com/releases/157189.php>

APA
Urotoday. (2009, July 12). "Ductal Adenocarcinoma Of The Prostate: Clinical Features And Implications After Local Therapy." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/157189.php.

Please note: If no author information is provided, the source is cited instead.



Add Your Opinion On This Article

'Ductal Adenocarcinoma Of The Prostate: Clinical Features And Implications After Local Therapy'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Your Name:*
E-mail Address:*
Your Opinion Title:*
Opinion:*
This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*

* Fields marked with a * need to be filled in before you hit the submit button.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Prostate / Prostate Cancer

What Is Prostate Cancer?

Prostate cancer is a disease which only affects men. Cancer begins to grow in the prostate - a gland in the male reproductive system. The word "prostate" comes from Medieval Latin prostate and Medieval French prostate. Read more...

Most Popular Articles



Follow Our Prostate News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Prostate / Prostate Cancer Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »